Semaglutide was associated with a 14% lower risk of primary composite outcomes in patients with metabolic dysfunction-associated steatotic liver disease ().
In a study of 20,384 patients, semaglutide users had 31.8 events per 10,000 person-years compared to 36.6 events for users of other GLP-1 receptor agonists.
Semaglutide was linked to a 32% reduction in all-cause mortality (adjusted hazard ratio 0.68).
The risk of major adverse liver outcomes was reduced by 21% for those using semaglutide (adjusted hazard ratio 0.79).
Benefits of semaglutide were consistent across various subgroups including age, sex, obesity status, and diabetes status.
Comparative effectiveness showed semaglutide outperforming dulaglutide and liraglutide in terms of clinical outcomes.
Simplified
OBJECTIVES: Metabolic dysfunction-associated steatotic liver disease () is the most prevalent chronic liver disease worldwide. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) show promise in MASLD treatment, the comparative effectiveness of semaglutide versus other GLP-1RAs remains unclear. This study aimed to compare clinical outcomes between semaglutide and other GLP-1RAs in patients with MASLD.
METHODS: Using the TriNetX Research Network database, we conducted a retrospective cohort study of patients with MASLD newly prescribed GLP-1RAs between December 2017 and September 2023. The primary outcome was a composite of all-cause mortality, major adverse cardiovascular events, major adverse kidney events, and major adverse liver outcomes. Secondary outcomes included the individual components of the primary outcome.
RESULTS: After propensity score matching, 20,384 patients were included in each group. Compared to other GLP-1RAs, semaglutide was associated with a 14% lower risk of primary composite outcomes (31.8 vs. 36.6 events per 10,000 person-years; adjusted HR, 0.86; 95% CI: 0.80-0.93). Semaglutide users showed significantly reduced risks of all-cause mortality (aHR, 0.68; 95% CI: 0.59-0.80) and major adverse liver outcomes (aHR, 0.79; 95% CI: 0.66-0.94). Benefits were consistent across subgroups, including age, sex, obesity status, and diabetes status. Comparative analyses showed superior outcomes with semaglutide versus dulaglutide (aHR, 0.88; 95% CI: 0.81-0.96) and liraglutide (aHR, 0.83; 95% CI: 0.71-0.97).
CONCLUSIONS: In patients with MASLD, semaglutide use was associated with significantly better clinical outcomes compared to other GLP-1RAs, particularly in reducing mortality and major adverse liver outcome risks. These findings suggest semaglutide may be the preferred choice for MASLD treatment.
Key numbers
0.86
Lower Risk of Composite Outcomes
for primary composite outcomes comparing semaglutide to other GLP-1RAs.
0.68
Reduction in All-Cause Mortality
for all-cause mortality comparing semaglutide to other GLP-1RAs.
0.79
Reduction in Major Adverse Liver Outcomes
for major adverse liver outcomes comparing semaglutide to other GLP-1RAs.
Full Text
We can’t show the full text here under this license.
